Johnson & Johnson

Abbvie

Protagonist

Johnson & Johnson Partners with Protagonist Therapeutics to Compete with AbbVie's Skyrizi

AbbVie Expands "Striking Out Cancer" Campaign League-Wide with MLB Partnership

AbbVie Enters Obesity Market with Positive ABBV-295 Phase 1 Results

Chevron

Smartest Dividend Stocks to Buy with $2,000 Right Now: AbbVie and Chevron

AbbVie Partners with Alloy Therapeutics to Develop Next-Gen Antibody Platform

Catalyst<ul> <li>Most analysts rate ABBV Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Fund flows show negative trends across all size categories, indicating selling pressure.</li></ul>

Key Factors

Abbvie reported positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing dose-dependent weight reductions. Abbvie's stock dipped below its 50-day moving average on March 13, 2026, but remains above the 200-day SMA, indicating a stable long-term uptrend. Abbvie's shares closed with a 0.07% decline on March 23, 2026, trading at 1.5 billion shares with a 73.79% drop in volume compared to the previous day.

Recent Updates

ABBV News